Familial colorectal cancer type X: Genetic profiles and phenotypic features

Modern Pathology

Volumn 28, Issue 1, 2015, Pages 30-36

  Dominguez Valentin, Mev ^a,b   Therkildsen, Christina ^a   Da Silva, Sabrina ^c   Nilbert, Mef ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LUND UNIVERSITY   (Sweden)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Epigenetic; familial colorectal cancer type X; genotype; pathways; phenotype

Indexed keywords

ARTICLE; CLINICAL FEATURE; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HEREDITARY COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; COLORECTAL TUMOR; GENETIC PREDISPOSITION; GENETICS; GENOTYPE;

COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; PHENOTYPE;

EID: 84920703226     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.49     Document Type: Article

References (81)

1. Patel SG, Ahnen DJ. Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep 2012;14:428-438.
2. Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005;293:1986-1994.
3. Balmana J, Castells A, Cervantes A, et al. Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. Ann Oncol 2010;5:v78-v81.
4. Woods MO, Younghusband HB, Parfrey PS, et al. The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease. Gut 2010;59:1369-1377.
5. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009;18:1688-1694.
6. Castells A, Giardiello FM. Familial colorectal cancer screening: so close, so far. Gastroenterology 2013;144: 492-494.
7. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600.
8. Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-665.
9. Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-669.
10. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003;348:791-799.
11. Amos CI, Keitheri-Cheteri MB, Sabripour M, et al. Genotype-phenotype correlations in Peutz-Jeghers syndrome. J Med Genet 2004;41:327-333.
12. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998;280:1086-1088.
13. Sweet K, Willis J, Zhou XP, et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005;294:2465-2473.
14. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-425.
15. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-1456.
16. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005;293:1979-1985.
17. Trano G, Sjursen W, Wasmuth HH, et al. Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study. Br J Cancer 2010;102: 482-488.
18. Lynch HT, Lynch PM. Molecular screening for the Lynch syndrome-better than family history? N Engl J Med 2005;352:1920-1922.
19. Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007;44:353-362.
20. Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology 2013;44:926-932; e1; quiz e13-4.
21. Koh PK, Kalady M, Skacel M, et al. Familial colorectal cancer type X: polyp burden and cancer risk stratification via a family history score. ANZ J Sur 2011;81: 537-542.
22. Francisco I, Albuquerque C, Lage P, et al. Familial colorectal cancer type X syndrome: two distinct molecular entities? Fam Cancer 2011;10:623-631.
23. Segui N, Pineda M, Navarro M, et al. GALNT12 is not a major contributor of familial colorectal cancer type X. Hum Mutat 2014;35:50-52.
24. Therkildsen C, Jonsson G, Dominguez-Valentin M, et al. Gain of chromosomal region 20q and loss of 18 discriminates between Lynch syndrome and familial colorectal cancer. Eur J Cancer 2013;49:1226-1235.
25. Dominguez-Valentin M, Therkildsen C, Veerla S, et al. Distinct gene expression signatures in lynch syndrome and familial colorectal cancer type x. PLoS One 2013; 8:e71755.
26. Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012;308:1555-1565.
27. Peltomaki P, Gao X, Mecklin JP. Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs shared predisposing mutations. Fam Cancer 2001;1:9-15.
28. Nieminen TT, Abdel-Rahman WM, Ristimaki A, et al. BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 2011;141:e23-e26.
29. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-2087; e3.
30. Jenkins MA, Southey MC, Giles GG, et al. Rationale for, and approach to, studying modifiers of risk in persons with a genetic predisposition to colorectal cancer. Curr Oncol Rep 2007;9:202-207.
31. Lindor NM. Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome. Surg Oncol Clin N Am 2009;18:637-645.
32. de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 2010;28:3380-3387.
33. Lynch HT, Lynch JF, Attard TA. Diagnosis and management of hereditary colorectal cancer syndromes: Lynch syndrome as a model. CMAJ 2009;181:273-280.
34. Balmana J, Balaguer F, Cervantes A, et al. Familial riskcolorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2013;6:vi73-vi80.
35. Mueller-Koch Y, Vogelsang H, Kopp R, et al. Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer. Gut 2005;54:1733-1740.
36. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007;133:48-56.
37. Klarskov L, Holck S, Bernstein I, et al. Hereditary colorectal cancer diagnostics: morphological features of familial colorectal cancer type X versus Lynch syndrome. J Clin Pathol 2012;65:352-356.
38. Llor X, Pons E, Xicola RM, et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res 2005;11:7304-7310.
39. Ku CS, Cooper DN, Wu M, et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 2012;25:1055-1068.
40. Bernstein IT, Myrhoj T. Surveillance for urinary tract cancer in Lynch syndrome. Fam Cancer 2013;12: 279-284.
41. Houlston RS, Webb E, Broderick P, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 2008;40:1426-1435.
42. Middeldorp A, Jagmohan-Changur SC, van der Klift HM, et al. Comprehensive genetic analysis of seven large families with mismatch repair proficient colorectal cancer. Genes Chromosomes Cancer 2010;49: 539-548.
43. Win AK, Hopper JL, Buchanan DD, et al. Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers? Eur J Cancer 2013;49:1578-1587.
44. DeRycke MS, Gunawardena SR, Middha S, et al. Identification of novel variants in colorectal cancer families by high-throughput exome sequencing. Cancer Epidemiol Biomarkers Prev 2013;22:1239-1251.
45. Clarke E, Green RC, Green JS, et al. Inherited deleterious variants in GALNT12 are associated with CRC susceptibility. Hum Mutat 2012;33:1056-1058.
46. Venkatachalam R, Verwiel ET, Kamping EJ, et al. Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients. Int J Cancer 2011;129:1635-1642.
47. Kontham V, von Holst S, Lindblom A. Linkage analysis in familial non-Lynch syndrome colorectal cancer families from Sweden. PLoS One 2013;8:e83936.
48. Abuli A, Bessa X, Gonzalez JR, et al. Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype. Gastroenterology 2010;139:788-796; e1-6.
49. Ogino S, Kawasaki T, Nosho K, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008;122:2767-2773.
50. Goel A, Nguyen TP, Leung HC, et al. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int J Cancer 2011;128:869-878.
51. Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14:16365-16385.
52. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. Cancers (Basel) 2013;5:676-713.
53. Joensuu EI, Abdel-Rahman WM, Ollikainen M, et al. Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res 2008;68:4597-4605.
54. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011;6:479-507.
55. Antelo M, Balaguer F, Shia J, et al. A high degree of LINE-1 hypomethylation is a unique feature of earlyonset colorectal cancer. PLoS One 2012;7:e45357.
56. Pavicic W, Joensuu EI, Nieminen T, et al. LINE-1 hypomethylation in familial and sporadic cancer. J Mol Med 2012;90:827-835.
57. Goel A, Xicola RM, Nguyen TP, et al. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 2010;138:1854-1862.
58. Ogino S, Nishihara R, Lochhead P, et al. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst 2012;105:130-140.
59. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol 2013;26:465-484.
60. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8:686-700.
61. Li F, Mao G, Tong D, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSa. Cell 2013;153:590-600.
62. Abdel-Rahman WM, Ollikainen M, Kariola R, et al. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene 2005;24:1542-1551.
63. Middeldorp A, van Eijk R, Oosting J, et al. Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas. Int J Cancer 2012;130:837-846.
64. Wilson CH, McIntyre RE, Arends MJ, et al. The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/\+) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene 2010;29:4567-4575.
65. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-274.
66. Sillars-Hardebol AH, Carvalho B, Tijssen M, et al. TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut 2012;61:1568-1575.
67. Jin YT, Ying XX, Hu YH, et al. aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa-overexpressed breast cancer. Oncol Res 2008;17:59-68.
68. Lips EH, van Eijk R, de Graaf EJ, et al. Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis. BMC Cancer 2008;8:314.
69. Sanchez-de-Abajo A, de la Hoya M, van Puijenbroek M, et al. Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. Clin Cancer Res 2007;13:5729-5735.
70. Danielsen SA, Cekaite L, Agesen TH, et al. Phospholipase C isozymes are deregulated in colorectal cancer-insights gained from gene set enrichment analysis of the transcriptome. PLoS One 2011;6:e24419.
71. Watanabe T, Kobunai T, Toda E, et al. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res 2006;66:9804-9808.
72. Bertucci F, Salas S, Eysteries S, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004;23:1377-1391.
73. Dunican DS, McWilliam P, Tighe O, et al. Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by highdensity cDNA array hybridization. Oncogene 2002;21: 3253-3257.
74. Yuan Z, Sotsky Kent T, Weber TK. Differential expression of DOC-1 in microsatellite-unstable human colorectal cancer. Oncogene 2003;22:6304-6310.
75. Kim H, Nam SW, Rhee H, et al. Different gene expression profiles between microsatellite instabilityhigh and microsatellite stable colorectal carcinomas. Oncogene 2004;23:6218-6225.
76. Banerjea A, Ahmed S, Hands RE, et al. Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer 2004;3:21.
77. Lee WS, Seo G, Shin HJ, et al. Identification of differentially expressed genes in microsatellite stable HNPCC and sporadic colon cancer. J Surg Res 2008; 144:29-35.
78. Maekawa M, Sugano K, Sano H, et al. Increased expression of cyclooxygenase-2 to-1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. Jpn J Clin Oncol 1998;28:421-426.
79. Kim SH, Park YY, Kim SW, et al. ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res 2011; 71:7010-7020.
80. Baba Y, Nosho K, Shima K, et al. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 2010;19:822-831.
81. Lau SK, Shields DJ, Murphy EA, et al. EGFR-mediated carcinoma cell metastasis mediated by integrin avb5 depends onactivation of c-Src and cleavage of MUC1. PLoS One 2012;7:e36753.